obesity drug news today glp-1 october 2025 oct 27 Weight loss with GLP-1 medicines does The Obesity-Drug Revolution Is Stalling

PMID: 29168138 Solvent & Solubility In Vitro : H 2 O : 50 mg/mL ( 310.17 mM ) * "" means soluble, but saturation unknown

It is also notably stable in gastric juice, which is unusual for a peptide of this size

These new technologies have transformed liposuction into a much safer and less invasive procedure

Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial

Discovery of a lysophospholipid acyltransferase family essential for membrane asymmetry and diversity

The treatment duration ranged from 40 days to 12 weeks, and daily doses of ALC varied from 13 g/day